Company

Bank

Analyst

Coverage

Opinion

Wk chg

7/19 cls

bluebird bio Inc. (NASDAQ:BLUE)

JPMorgan

Cory Kasimov

New

Overweight

11%

$33.99

Wedbush

David Nierengarten

New

Outperform

Kasimov set a $44 target. He believes bluebird's gene therapy platform and strategy of pursuing monogenic Orphan diseases, is "one of the more potentially transformative and disruptive companies" he's come across in some time. The company already has two clinical proof-of-concept programs, including Lenti-D for childhood cerebral adrenoleukodystrophy (ALD). Late this year, bluebird plans to start Phase II/III testing of Lenti-D, a hematopoietic stem cell therapy with a lentiviral vector encoding the wild-type gene for the ALD protein. LentiGlobin, a lentiviral vector encoding the human beta globin gene delivered into a patient's hematopoietic stem cells in the bone marrow, is in Phase I/II testing to treat beta-thalassemia and sickle cell disease. Kasimov expects interim data from the pipeline as early as next year (see BioCentury, June 24 & July 1). bluebird raised $116.1M in a June IPO.